RenovoRx reports Q2 2022 net loss of $2.6M; cash $10.8M; Phase 3 interim analysis expected Q4 2022

RenovoRx, Inc.

2023-Q2 EPS reported -$0.62

Net loss of $2.6M for Q2 2022 vs $1.3M in Q2 2021; R&D expense $1.4M vs $0.5M.
Cash and equivalents and short-term marketable securities of $10.8M as of June 30, 2022.
Phase 3 TIGeR-PaC first prospective interim analysis expected in Q4 2022.
Protocol for Phase 2/3 trial in extrahepatic cholangiocarcinoma submitted to FDA; first patient enrollment planned Q4 2022.
Appointed James Ahlers as CFO and Ron Kocak as VP & Controller in July 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.